<p>The most successful cancer treatment of the past decade uses engineered immune cells — called CAR T-cells — that are programmed to hunt and destroy tumours. Scientists have now adapted that same approach for <strong>Alzheimer's disease</strong>, targeting the amyloid plaques that gradually destroy the brain.</p>
<p>The results, published in the journal <em>Science</em> in March 2026, are striking: a single injection of the new therapy completely prevented plaque formation in young mice, and cut existing plaque levels by approximately half in older mice already showing significant Alzheimer's pathology.</p>
<h2>CAR-Astrocytes: Teaching the Brain to Clean Itself</h2>
<p>The innovation comes from researchers at Washington University School of Medicine in St. Louis, led by professors Marco Colonna and David Holtzman. Instead of engineering T-cells (which don't normally live in the brain), they engineered <strong>astrocytes</strong> — the brain's most abundant support cells, which are naturally present throughout brain tissue.</p>
<p>They gave these astrocytes a chimeric antigen receptor (CAR) — a molecular "homing device" that instructs the cell to seek out, latch onto, and degrade amyloid-beta, the toxic protein that aggregates into the plaques that define Alzheimer's. The resulting CAR-astrocytes act as a "living drug": once introduced, they persist and keep working without further doses.</p>
<h2>What the Mice Results Showed</h2>
<p>In Alzheimer's mouse models, the effects were remarkable:</p> <ul> <li>In <strong>young mice</strong>, a single injection <strong>completely prevented</strong> amyloid plaque formation</li> <li>In <strong>older mice</strong> with existing plaques, a single injection <strong>reduced plaque levels by approximately 50%</strong></li> <li>The therapy also <strong>protected neurons</strong> from damage and <strong>reduced neuroinflammation</strong> — a secondary driver of Alzheimer's that existing treatments don't address</li> </ul>
<h2>Why This Is Different From Existing Treatments</h2>
<p>Current FDA-approved Alzheimer's drugs — lecanemab (Leqembi) and donanemab (Kisunla) — also clear amyloid plaques. But they require <strong>frequent intravenous infusions</strong> at hospital facilities, typically every two to four weeks, and carry serious risks including brain swelling and bleeding.</p>
<p>The CAR-astrocyte approach, if it translates to humans, would offer <strong>a single injection</strong> with potentially lasting effect. The cells are delivered to the brain using a harmless virus — a gene therapy technique already in clinical use — and are designed to self-sustain.</p>
<p>"This 'living drug' paradigm could eliminate the need for repeated high-dose infusions," the researchers wrote — a significant advantage for both patients and the healthcare system.</p>
<h2>The Road Ahead</h2>
<p>This is preclinical research in mice, and the path from mouse model to human trial is long. The researchers acknowledge that further work is needed to optimise delivery, ensure long-term safety, and confirm that the approach translates to the more complex human brain.</p>
<p>But the principle — using the brain's own most abundant cells, armed with precision targeting technology, to clear its own debris — is elegant and scientifically sound. A patent has been filed. Human trials are the next step.</p>
<p>Alzheimer's disease affects more than 55 million people worldwide. For a condition where current treatments can only slow decline at best, a therapy that might one day prevent or dramatically reverse it represents exactly the kind of breakthrough those 55 million people — and their families — are waiting for.</p>
<p><em>Sources: Science (March 2026) · Washington University School of Medicine · SingularityHub · Neuroscience News · ScienceDaily · Technology Networks</em></p>
